WO2014069385A1 - Composition pour usage externe - Google Patents

Composition pour usage externe Download PDF

Info

Publication number
WO2014069385A1
WO2014069385A1 PCT/JP2013/079077 JP2013079077W WO2014069385A1 WO 2014069385 A1 WO2014069385 A1 WO 2014069385A1 JP 2013079077 W JP2013079077 W JP 2013079077W WO 2014069385 A1 WO2014069385 A1 WO 2014069385A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
acid
weight
viscosity
external use
Prior art date
Application number
PCT/JP2013/079077
Other languages
English (en)
Japanese (ja)
Inventor
映美 武本
幸恵 武田
Original Assignee
ロート製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ロート製薬株式会社 filed Critical ロート製薬株式会社
Priority to CN201380056741.5A priority Critical patent/CN104780902A/zh
Priority to JP2014544486A priority patent/JP6386911B2/ja
Publication of WO2014069385A1 publication Critical patent/WO2014069385A1/fr
Priority to HK15111571.7A priority patent/HK1210709A1/xx

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a composition containing an acidic mucopolysaccharide, wherein the properties of the acidic mucopolysaccharide are maintained stably.
  • Skin has a reduced water retention function or skin barrier function due to various factors such as exposure to ultraviolet light, external factors such as changes in temperature or humidity, and internal factors such as aging. Various troubles such as dryness, itchiness, rash, soreness and sweat are caused. In order to improve these symptoms, it is first to remove the cause, but it is effective to normalize the moisture retention function or the skin barrier function by applying a pharmaceutical or cosmetic containing a moisturizing ingredient.
  • mucopolysaccharides such as hyaluronic acid, chondroitin sulfate, heparin, dermatan sulfate, heparan sulfate, and keratan sulfate are used.
  • hyaluronic acid will be described.
  • Hyaluronic acid is a mucopolysaccharide composed of glucuronic acid and N-acetylglucosamine, and is present in a large amount in the dermis as a bonding substance that fills cells and fibers in vivo. It is a substance that has been confirmed to exist in the epidermis and has high water retention and viscoelasticity. Because of these properties, it is used as a component such as eye drops for treating corneal epithelial disorders and injections for treating knee osteoarthritis in the medical field, and as a moisturizing agent in the cosmetic field.
  • mucopolysaccharide is a polysaccharide thickener that is widely used as a moisturizer for external preparations.
  • a surfactant is added to an external preparation from the viewpoint of formulation or use feeling, but mucopolysaccharides are known to decrease in viscosity when used in combination with a surfactant. This decrease in viscosity is particularly noticeable when the composition is exposed to light or heat.
  • a moist and moist feeling that is a feeling of use of the composition containing the mucopolysaccharide is reduced.
  • the moisture retention function of the composition containing mucopolysaccharide is impaired.
  • Patent Document 1 teaches that an external preparation for skin containing high molecular weight hyaluronic acid, low molecular weight hyaluronic acid, polyhydric alcohol, and edetate salt is excellent in moisture retention performance because the decrease in viscosity over time is suppressed.
  • Patent Document 2 shows that, by adding a specific vegetable oil to a mucosa-applied composition containing hyaluronic acid or a salt thereof, a decrease in viscosity of the composition is suppressed even when a surfactant is included. I teach.
  • patent document 3 teaches that the viscosity fall of a composition is suppressed by mix
  • compositions described in these documents are not practically sufficient to suppress the decrease in the viscosity of the mucopolysaccharide over time and the accompanying deterioration in the feeling of use and moisturizing performance.
  • composition of patent document 2 and 3 mix
  • the present invention provides an external composition containing an acidic mucopolysaccharide, in which a decrease in viscosity with time and a decrease in use feeling and moisturizing performance associated therewith over time are practically sufficiently suppressed. This is the issue.
  • the present inventor repeated research to solve the above problems, and when a compound having a polyoxyalkylene group is blended with acidic mucopolysaccharide, the viscosity of the composition tends to decrease over time. It has been found that, by blending, a decrease in viscosity of the composition with time is remarkably suppressed.
  • Item 1 An external composition comprising (a) acidic mucopolysaccharide, (b) a compound having a polyoxyalkylene group, and (c) a hydroxyalkylurea.
  • Item 2. The composition for external use according to Item 1, wherein the hydroxyalkylurea is N- (2-hydroxyethyl) urea.
  • Item 3. The topical composition according to Item 1 or 2, wherein the acidic mucopolysaccharide is selected from the group consisting of hyaluronic acid, chondroitin sulfate, and salts thereof.
  • Item 4. Item 4.
  • Item 5. The composition for external use according to any one of Items 1 to 4, comprising 0.0001 to 2000 parts by weight of hydroxyalkylurea per 1 part by weight of the compound having a polyoxyalkylene group.
  • Item 6. The composition for external use according to any one of Items 1 to 5, comprising 0.01 to 10,000 parts by weight of hydroxyalkylurea per 1 part by weight of acidic mucopolysaccharide.
  • Item 8. The composition for external use according to any one of Items 1 to 7, comprising 0.001 to 30% by weight of hydroxyalkylurea based on the total amount of the composition.
  • Item 9. The external composition according to any one of Items 1 to 8, wherein the compound having a polyoxyalkylene group is contained in an amount of 0.01 to 20% by weight based on the total amount of the composition.
  • Item 11. Item 10.
  • composition for external use according to any one of Items 1 to 9, which is for imparting a tight feeling to the skin.
  • Item 12. A method for moisturizing the skin by applying an external composition containing (a) an acidic mucopolysaccharide, (b) a compound having a polyoxyalkylene group, and (c) a hydroxyalkylurea to human skin, or the skin A method of giving a moist, plump or sticky feeling.
  • Item 13 A method according to claim 12, which is a non-therapeutic method.
  • a combination of (a) acidic mucopolysaccharide, (b) a compound having a polyoxyalkylene group, and (c) hydroxyalkylurea provides a moisturizing agent, or a moist, fluffy or sticky feeling to the skin.
  • Item 15. (A) an acidic mucopolysaccharide, (b) a compound having a polyoxyalkylene group, and (c) for the manufacture of a skin moisturizer or an agent for imparting moist, plump or moist feeling to the skin, and (c) Combination use of hydroxyalkylurea.
  • Acid mucopolysaccharide is a general-purpose component added to the composition for external use in order to give viscosity and moisture retention performance.
  • a compound having a polyoxyalkylene group is widely used as a component of an external composition because it functions as, for example, a nonionic surfactant.
  • a compound having a polyoxyalkylene group is added to a composition containing acidic mucopolysaccharide, the viscosity of the acidic mucopolysaccharide is impaired, particularly when the composition is exposed to heat or light. Will fall.
  • the composition for external use of the present invention includes a hydroxyalkyl urea in addition to the acidic mucopolysaccharide and the compound having a polyoxyalkylene group, so that the viscosity of the composition is reduced even when exposed to heat or light. Is significantly suppressed. As a result, the moisturizing performance is maintained for a long time, and the skin can be moist, fluffy and moist for a long time. In particular, a sticky feeling can be imparted.
  • the vertical axis represents relative viscosity (%). It is a figure which shows the viscosity fall inhibitory effect of the composition by hydroxyethyl urea. The vertical axis represents relative viscosity (%). It is a figure which shows the viscosity fall inhibitory effect of the composition by hydroxyethyl urea. The vertical axis represents relative viscosity (%).
  • composition for external use of the present invention is a composition comprising (a) an acidic mucopolysaccharide, (b) a compound having a polyoxyalkylene group, and (c) a hydroxyalkylurea.
  • Acid mucopolysaccharide is a polysaccharide containing an amino sugar and uronic acid in its basic skeleton. Specific examples of the acidic mucopolysaccharide include hyaluronic acid, chondroitin sulfate, heparin, heparin-like substance, dermatan sulfate, heparan sulfate, and keratan sulfate I and II.
  • the acidic mucopolysaccharide may be a natural product, a natural product decomposed by a physical means such as acid or alkali, enzyme, ultrasonic wave or shear, or a natural product derivative.
  • hyaluronic acid is a natural polymeric hyaluronic acid that is hydrolyzed in the presence of an acid such as hydrochloric acid, treated with an enzyme such as hyaluronidase, or physically by ultrasound or shear. It may be decomposed hyaluronic acid prepared by cutting.
  • hyarooligo Korean Chemical Company
  • Natural derivatives include acetylated hyaluronic acid, hydroxypropyltrimonium hyaluronate, and the like.
  • the acidic mucopolysaccharide may be a natural product, a degradation product of a natural product, or a salt of each of these derivatives.
  • the salt may be a pharmaceutically or biologically acceptable salt, for example, an alkali metal salt such as sodium or potassium; an alkaline earth metal salt such as magnesium or calcium; a zinc salt; an ammonium salt; Examples thereof include alkanolamine salts such as monoethanolamine. Among these, alkali metal salts are preferable, and sodium salts are more preferable.
  • acidic mucopolysaccharide salts include sodium hyaluronate, potassium hyaluronate, calcium hyaluronate, magnesium hyaluronate, zinc hyaluronate, ammonium hyaluronate, monoethanolamine hyaluronate, sodium acetylated hyaluronate, acetylated Potassium hyaluronate, calcium acetylated hyaluronate, magnesium acetylated hyaluronate, zinc acetylated hyaluronate, ammonium acetylated hyaluronate, monoethanolamine acetylated hyaluronate, sodium chondroitin sulfate, potassium chondroitin sulfate, sodium dermatan sulfate, dermatan sulfate Potassium, chitosan ascorbic acid, chitosan
  • An acidic mucopolysaccharide can be used singly or in combination of two or more.
  • the origin of the acidic mucopolysaccharide is not particularly limited as long as it can be used in the fields of pharmaceuticals, quasi drugs, and cosmetics.
  • the average molecular weight of the acidic mucopolysaccharide is not particularly limited, and is, for example, about 1,000 to 4,000,000, preferably about 1,000 to 3,000,000, more preferably about 5,000 to 3,000,000, particularly preferably about 5,000 to 2,000,000. is there.
  • the content of the acidic mucopolysaccharide in the composition for external use is preferably 0.000001% by weight or more, more preferably 0.001% by weight or more, and still more preferably 0.01% by weight or more based on the total amount of the composition. preferable. If it is this range, sufficient viscosity and moisture retention performance can be given to an external composition. Further, the content of the acidic mucopolysaccharide in the composition for external use is preferably 1% by weight or less, more preferably 0.5% by weight or less, and even more preferably 0.25% by weight or less based on the total amount of the composition. preferable. If it is this range, stickiness will be suppressed and a favorable usability
  • the polyoxyalkylene group is a functional group represented by the following general formula (1).
  • m is, for example, 1 to 4, preferably 2 to 4.
  • Specific examples include a polyoxymethylene group, a polyoxyethylene group, a polyoxypropylene group, and a polyoxybutylene group.
  • n is, for example, 2 to 150, preferably 5 to 100, and more preferably 10 to 30.
  • a typical example of a compound having a polyoxyalkylene group is polyoxyalkylene glyceryl ether in which a polyoxyalkylene group is ether-bonded to 1 to 3 of 3 carbons of glycerin.
  • Fatty acids may be ester-bonded to carbon to which no polyoxyalkylene group is bonded.
  • polyoxymethylene glyceryl ether polyoxyethylene glyceryl ether, polyoxyethylene glyceryl ether, polyoxypropylene glyceryl ether, polyoxybutylene glyceryl ether, polyoxymethylene / polyoxyethylene glyceryl ether, polyoxymethylene / polypropylene glyceryl ether, polyoxy Methylene polyoxybutylene glyceryl ether, polyoxyethylene polyoxypropylene glyceryl ether, polyoxyethylene polyoxybutylene glyceryl ether, polyoxypropylene polyoxybutylene glyceryl ether, polyoxymethylene polyoxyethylene polyoxypropylene glyceryl Ether, polyoxymethylene, polyoxyethylene, polyoxybutylene glyceryl ether , Polyoxypropylene polyoxyethylene polyoxybutylene glyceryl ether, polyoxypropylene polyoxymethylene-polyoxybutylene glyceryl ether and the like.
  • glyceryl ether having a polyoxybutylene group is preferable, and polyoxymethylene, polyoxyethylene, polyoxybutylene glyceryl ether, polyoxybutylene, polyoxyethylene, polyoxypropylene glyceryl ether, polyoxypropylene, polyoxymethylene, poly Oxybutylene glyceryl ether is more preferred, and polyoxybutylene / polyoxyethylene / polyoxypropylene glyceryl ether is even more preferred.
  • Examples of commercially available products of polyoxybutylene, polyoxyethylene, and polyoxypropylene glyceryl ether include, for example, Willbride S-753 (manufactured by NOF Corporation; polyoxybutylene polyoxyethylene polyoxypropylene glyceryl ether (3B.O) (8E .O) (5P.O)) and the like can be used.
  • Polyoxyalkylene glyceryl ethers containing fatty acid residues include polyoxyethylene glyceryl distearate, polyoxyethylene glyceryl tristearate, polyoxyethylene glyceryl isostearate, polyoxyethylene glyceryl triisostearate, polyoxyethylene isostearate Examples thereof include glyceryl, polyoxyethylene glyceryl diisostearate, polyoxyethylene glyceryl triisostearate, polyoxyethylene glyceryl trioleate, and polyoxyethylene monococonut oil fatty acid glyceryl.
  • a compound having a polyoxyalkylene group can be used singly or in combination of two or more.
  • the content of the compound having a polyoxyalkylene group in the external composition is preferably 0.01% by weight or more, more preferably 0.05% by weight or more, and more preferably 0.1% by weight or more based on the total amount of the composition. Is even more preferred. If it is this range, normally the effect
  • Hydroxyalkylurea refers to a compound in which at least one hydrogen atom of urea is substituted with a hydroxyalkyl group. That is, the hydroxyalkyl urea referred to in the present invention is a compound represented by the following general formula (2).
  • R 1 R 2 N—CO—NR 3 R 4 (2) (Wherein R 1 , R 2 , R 3 , and R 4 each independently represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, or a hydroxyalkyl group having 2 to 6 carbon atoms, and (At least one of R 1 , R 2 , R 3 , and R 4 is a hydroxyalkyl group having 2 to 6 carbon atoms.)
  • hydroxyalkyl group examples include a hydroxyethyl group, a hydroxypropyl group, a hydroxybutyl group, a dihydroxybutyl group, a hydroxypentyl group, and a hydroxyhexyl group. Of these, a hydroxyethyl group is preferable. More specifically, hydroxyalkylureas include N- (2-hydroxyethyl) urea, N- (2-hydroxypropyl) urea, N- (3-hydroxypropyl) urea, N- (2,3-dihydroxypropyl).
  • Hydroxyalkyl urea can be used singly or in combination of two or more.
  • the content of hydroxyalkyl urea in the composition for external use is preferably 0.001% by weight or more, more preferably 0.01% by weight or more, and still more preferably 0.1% by weight or more based on the total amount of the composition. .
  • the content of hydroxyalkyl urea in the external composition is preferably 30% by weight or less, more preferably 20% by weight or less, and still more preferably 10% by weight or less based on the total amount of the composition. If it is this range, the effect of said this invention will fully be acquired.
  • the ratio of the content of hydroxyalkylurea to the content of the compound having a polyoxyalkylene group is preferably 0.0001 part by weight or more with respect to 1 part by weight of the compound having a polyoxyalkylene group, and 0.01 wt. Part or more is more preferable, and 0.1 part by weight or more is even more preferable. Within this range, the effects of the present invention (suppression of the time-dependent decrease in the viscosity, moisture retention performance, moist feeling and moist feeling imparting performance of the composition) can be sufficiently obtained.
  • the ratio of the hydroxyalkylurea content to the content of the compound having a polyoxyalkylene group is preferably 500 parts by weight or less, more preferably 200 parts by weight or less, relative to 1 part by weight of the compound having a polyoxyalkylene group. Preferably, 100 parts by weight or less is even more preferable. If it is this range, the effect of said this invention will fully be acquired.
  • the ratio of the content of hydroxyalkylurea to the content of acidic mucopolysaccharide is preferably 0.01 parts by weight or more, more preferably 1 part by weight or more, with respect to 1 part by weight of acidic mucopolysaccharide. Part or more is even more preferable. Within this range, the effects of the present invention (suppression of the time-dependent decrease in the viscosity, moisture retention performance, moist feeling and moist feeling imparting performance of the composition) can be sufficiently obtained.
  • the ratio of the content of hydroxyalkylurea to the content of acidic mucopolysaccharide is preferably 10,000 parts by weight or less, more preferably 500 parts by weight or less, and more preferably 100 parts by weight or less with respect to 1 part by weight of acidic mucopolysaccharides. Is even more preferred. If it is this range, the effect of said this invention will fully be acquired.
  • composition for external use of the present invention is prepared by mixing the components (a) to (c) described above together with a base or carrier that can be used in cosmetics, and optionally additives and other active ingredients, For example, it can be set as the external composition for cosmetics.
  • the property of the composition is not particularly limited, and can be a liquid, fluid, or semi-solid preparation, for example, liquid, suspension, emulsion, cream, ointment, gel, liniment.
  • a preparation such as a lotion, an aerosol, or a sheet obtained by impregnating a nonwoven fabric with a chemical.
  • emulsions, creams, emulsions, ointments, gels, and lotions are preferred, and creams, emulsions, ointments, and gels are particularly preferred.
  • cosmetics are not particularly limited, and lotions, emulsions, gels, creams, serums, sunscreen cosmetics, basic cosmetics such as packs, masks, hand creams, body lotions, body creams; Cosmetics, makeup removers, body shampoos, shampoos, rinses, cleaning cosmetics such as treatments; foundations, makeup cosmetics such as various colors, and the like.
  • paraffin As a base or carrier bases or carriers, paraffin, liquid paraffin, squalane, white wax, hydrocarbon gel (such as Plastibase), ozokerite, ceresin, vaseline, hard fat, microcrystalline wax, alpha-olefin oligomers, light liquid Hydrocarbons such as paraffin; fatty acids such as lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, isostearic acid; glyceryl tri-2-ethylhexanoate (trioctanoin), tri (caprylic acid / capric acid) Tri-fatty acid glycerides such as glyceryl; higher alcohols such as cetanol, stearyl alcohol, and behenyl alcohol; methyl polysiloxane, highly polymerized methyl polysiloxane, dimethylsiloxane methyl (polyoxyethylene) siloxane -Methyl (polyoxypropylene) siloxane cop
  • hydrocarbons especially ⁇ -olefin oligomers, squalane, light liquid paraffin, liquid paraffin
  • tri fatty acid glycerides especially glyceryl tri-2-ethylhexanoate, tri (caprylic acid / capric acid) glyceryl
  • higher alcohols In particular, cetanol, stearyl alcohol, behenyl alcohol
  • silicone oil especially methylpolysiloxane, alkyl acrylate copolymer methylpolysiloxane ester, cross-linked methylpolysiloxane, decamethylcyclopentasiloxane, ethyltrisiloxane, methyltrimethicone, Methylsiloxane network polymer, polyoxyethylene / methylpolysiloxane copolymer, methylhydrogenpolysiloxane, triethoxysilylethylpolydimethylsiloxyethylhe
  • additives to be added to cosmetics for example, antioxidants, surfactants, thickeners, preservatives, pH adjustments, as long as the effects of the present invention are not impaired.
  • Agents, stabilizers, irritation reducers, preservatives, colorants, fragrances, pearlescent agents and the like can be added.
  • the antioxidant include dibutylhydroxytoluene, butylhydroxyanisole, sorbic acid, sodium sulfite, ascorbic acid, ascorbic acid derivatives, tocopherol, tocopherol derivatives, erythorbic acid, L-cysteine hydrochloride and the like.
  • surfactant examples include sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, diglycerol sorbitan penta-2-ethylhexylate, and diglycerol sorbitan tetra-2-ethylhexylate.
  • Sorbitan fatty acid esters such as propylene glycol monostearate; glycerin alkyl ethers; alkyl glucosides; amines such as stearylamine and oleylamine; polyoxyethylene-methylpolysiloxane copolymer, lauryl PEG Examples thereof include silicone surfactants such as -9 polydimethylsiloxyethyl dimethicone and PEG-9 polydimethylsiloxyethyl dimethicone.
  • thickener examples include guar gum, locust bean gum, carrageenan, xanthan gum, polyvinyl alcohol, polyvinyl pyrrolidone, carboxyvinyl polymer, alkyl methacrylate copolymer, polyethylene glycol, bentonite, alginic acid, macrogol, and cellulose series.
  • thickeners such as methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, and carboxyethylcellulose
  • preservatives and preservatives include benzoic acid, sodium benzoate, dehydroacetic acid, sodium dehydroacetate, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, butyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, paraoxybenzoic acid
  • examples include benzyl, methyl paraoxybenzoate, phenoxyethanol, benzyl alcohol, chlorobutanol, sorbic acid and its salt, chlorhexidine gluconate, alkanediol, and glycerin fatty acid ester.
  • pH adjusters examples include inorganic acids (hydrochloric acid, sulfuric acid, etc.), organic acids (lactic acid, sodium lactate, citric acid, sodium citrate, succinic acid, sodium succinate, etc.), inorganic bases (potassium hydroxide, sodium hydroxide, etc.) ) And organic bases (such as triethanolamine, diisopropanolamine, and triisopropanolamine).
  • Examples of the stabilizer include sodium polyacrylate, dibutylhydroxytoluene, butylhydroxyanisole, edetate and the like.
  • Examples of the irritation reducing agent include licorice extract and sodium alginate.
  • Additives can be used singly or in combination of two or more.
  • composition for external use of this invention can contain another active ingredient in the range which does not impair the effect of this invention.
  • active ingredients include, for example, moisturizing ingredients, anti-inflammatory ingredients, antibacterial ingredients, vitamins, peptides or derivatives thereof, cell activation ingredients, anti-aging ingredients, blood circulation promoting ingredients, keratin softening ingredients, whitening ingredients, astringent ingredients Etc.
  • Moisturizing ingredients include high molecular weight compounds such as collagen, elastin, keratin, chitin and chitosan; natural moisturizing factors such as sodium lactate, urea and sodium pyrrolidone carboxylate; lipids such as ceramide, cholesterol and phospholipid; chamomile extract , Plant extract extracts such as hamamelis extract, tea extract and perilla extract.
  • anti-inflammatory component examples include a plant-derived component (eg Comfrey), allantoin, glycyrrhizic acid or a derivative thereof, zinc oxide, pyridoxine hydrochloride, tocopherol acetate, salicylic acid or a derivative thereof, and ⁇ -aminocaproic acid.
  • plant-derived component eg Comfrey
  • allantoin glycyrrhizic acid or a derivative thereof
  • zinc oxide pyridoxine hydrochloride
  • tocopherol acetate e.glycyrrhizic acid or a derivative thereof
  • salicylic acid a derivative thereof
  • ⁇ -aminocaproic acid examples include a plant-derived component (eg Comfrey), allantoin, glycyrrhizic acid or a derivative thereof, zinc oxide, pyridoxine hydrochloride, tocopherol acetate, salicylic acid or a derivative thereof, and ⁇ -ami
  • Antibacterial or bactericidal components include ethanol, chlorhexidine, salicylic acid, benzalkonium chloride, acrinol, sulfur, resorcin, benzethonium chloride, adapalene, benzoyl peroxide, clindamycin, cresol, gluconic acid and its derivatives, popidone iodine, potassium iodide , Iodine, isopropylmethylphenol, triclocarban, triclosan, photosensitizer 101, photosensitizer 201, paraben, phenoxyethanol, 1,2-pentanediol, alkyldiaminoglycine hydrochloride, chlorhexidine gluconate, zinc paraphenolsulfonate, etc. It is done.
  • Vitamins include retinol, retinol acetate, retinol palmitate, etc., retinal, retinoic acid, methyl retinoic acid, ethyl retinoic acid, retinol retinoic acid, d- ⁇ -tocopheryl retinoate, ⁇ -tocopheryl retinoate Vitamin A such as ⁇ -tocopheryl retinoate; vitamin E such as dl- ⁇ -tocopherol, dl- ⁇ -tocopherol acetate, dl- ⁇ -tocopherol succinate, dl- ⁇ -tocopherol calcium succinate; riboflavin, Vitamin B2 such as flavin mononucleotide, flavin adenine dinucleotide, riboflavin butyrate, riboflavin tetrabutyrate, riboflavin 5'-sodium phosphate, riboflavin tetranicotinate Nicotin
  • Nicotinic acids pantothenic acid, calcium pantothenate, pantothenyl alcohol (panthenol), D-pantetheine, D-pantethine, coenzyme A, pantothenyl ethyl ether, etc.
  • Tennic acids biotins such as biotin and bioticin; vitamins C which are ascorbic acid derivatives such as ascorbic acid, sodium ascorbate, dehydroascorbic acid, sodium ascorbate phosphate sodium, magnesium ascorbate phosphate; carnitine, ferulic acid And vitamin-like agents such as ⁇ -lipoic acid and orotic acid.
  • Peptides or derivatives thereof include keratin-degrading peptide, hydrolyzed keratin, collagen, fish-derived collagen, atelocollagen, gelatin, elastin, elastin-degrading peptide, collagen-degrading peptide, hydrolyzed collagen, hydroxypropylammonium chloride hydrolyzed collagen, elastin-degrading peptide , Conchiolin degrading peptide, hydrolyzed conchiolin, silk proteolytic peptide, hydrolyzed silk, lauroyl hydrolyzed silk sodium, soy proteolytic peptide, hydrolyzed soy protein, wheat protein, wheat proteolytic peptide, hydrolyzed wheat protein, casein degrading peptide Acylated peptides (palmitoyl oligopeptide, palmitoyl pentapeptide, palmitoyl tetrapeptide, etc.).
  • Cell activating components include vitamins such as retinol, thiamine, riboflavin, pyridoxine hydrochloride, pantothenic acids; ⁇ -hydroxy acids such as glycolic acid and lactic acid; tannins, flavonoids, saponins, allantoins, and photosensitizer 301.
  • Antiaging components include pangamic acid, kinetin, ursolic acid, turmeric extract, sphingosine derivatives, silicon, silicic acid, N-methyl-L-serine, mevalonolactone, and the like.
  • Examples of the blood circulation promoting component include plants (for example, ginseng, ashitaba, arnica, ginkgo, fennel, enamel, Dutch oak, chamomile, roman chamomile, carrot, gentian, burdock, rice, hawthorn, shiitake, hawthorn, sorghum, nematode, Assembly, thyme, clove, chimney, spruce, spruce, spruce, carrot, garlic, butcher bloom, grape, button, maronier, melissa, yuzu, yokuinin, rosemary, rosehip, chimpy, touki, spruce, peach, apricot, walnut , A component derived from corn); and glucosyl hesperidin.
  • plants for example, ginseng, ashitaba, arnica, ginkgo, fennel, enamel, Dutch oak, chamomile, roman chamomile, carrot, gentian, burdock, rice, hawt
  • Examples of the keratin softening component include salicylic acid, glycolic acid, fruit acid, phytic acid, and sulfur.
  • Examples of the whitening component include ascorbic acid and its derivatives, arbutin, and tocopherol.
  • Examples of the astringent component include zinc paraphenol sulfonate, zinc oxide, menthol and ethanol.
  • the method of using the composition for external use of the present invention varies depending on the skin condition, age, sex, etc. of the subject of use, but may be the following method, for example. That is, an appropriate amount (for example, about 0.05 to 5 g) may be applied (applied, sprayed, affixed, etc.) to the skin several times a day (for example, about 1 to 5 times, preferably 1 to 3 times). Further, the composition may be applied so that the daily use amount of the acidic mucopolysaccharide is, for example, about 0.00005 to 0.025 g.
  • the composition for external use of the present invention can be applied to any skin such as face, neck, hand, foot, finger, torso, scalp and the like.
  • composition for external use of the present invention can be, for example, an external composition for moisturizing or imparting a moist, fluffy, or sticky feeling to the skin.
  • Sticky feeling means that after the preparation applied to the skin is lightly rubbed into the skin with a finger or palm, the applied preparation leaves a feeling left between the finger and the skin, and the finger or palm with the preparation extended. When the skin is separated from the skin, the skin to which the preparation is applied has a feeling of sticking to the finger or palm.
  • the present invention includes the above-described external composition of the present invention comprising (a) an acidic mucopolysaccharide, (b) a compound having a polyoxyalkylene group, and (c) a hydroxyalkylurea.
  • a method of moisturizing the skin by applying to the skin of hands, feet, fingers, torso, scalp, etc. (application, spraying, sticking, etc.) and a method of giving the skin a moist, plump or moist feeling Include. These methods can be non-therapeutic methods.
  • the method of using the external composition of the present invention in these methods is as described for the external composition of the present invention.
  • the present invention is a combination of (a) acidic mucopolysaccharide, (b) a compound having a polyoxyalkylene group, and (c) hydroxyalkylurea, a skin moisturizer, and a moist feeling on the skin, a fluffy feeling, Or includes non-therapeutic use as a moisturizing agent.
  • the present invention also includes (a) an acidic mucopolysaccharide and (b) a polyoxyalkylene group for the production of a skin moisturizing agent, and a moisturizing, plump or moisturizing agent for the skin. Includes the combined use of a compound and (c) a hydroxyalkylurea.
  • the components, dosage forms, and methods of using these agents are as described for the external composition of the present invention.
  • Test example 1 thermo stability test
  • Tables 1 and 2 below.
  • all the numerical values in Table 1 and Table 2 show weight%.
  • the viscosity measurement conditions are as follows.
  • the viscosity was measured using RE85 (Toki Sangyo). That is, the measurement temperature was 25 ° C. ⁇ 1 ° C., and the measurement was performed by measuring the viscosity every minute up to 3 minutes and using the average value of 3 times. Basically, as shown in FIG.
  • a sample is put into a gap of an angle ⁇ between the cone 1 and the flat disc 2 and the cone 1 or the flat disc 2 is rotated at a constant angular velocity ⁇ or torque T. Then, the torque or angular velocity received by the flat disk 2 or the cone 1 when the steady state is reached is measured, and the viscosity ⁇ of the sample is calculated by the following equation.
  • Test example 2 (light stability test) (1) Preparation of composition The composition of each Example and Comparative Example is shown in Table 4 below. In addition, all the numerical values in Table 4 show weight%.
  • the decrease in viscosity was expressed as a relative viscosity after irradiation with the unirradiated sample as 100%. That is, the relative viscosity of each composition was calculated by the following formula.
  • Relative viscosity (%) (viscosity of irradiated sample / viscosity of unirradiated sample) ⁇ 100
  • Latex Hydroxyethylurea 10.0 Concentrated glycerin 5.0 1,3-butylene glycol 5.0 Dipropylene glycol 5.0 Carboxyvinyl polymer 0.2 Acrylic acid / alkyl methacrylate copolymer 0.5 Polyoxybutylene polyoxyethylene polyoxypropylene glyceryl ether (3B.0) (8E.0) (5P.0) 3.0 Polyoxyethylene hydrogenated castor oil 3.0 Glyceryl stearate 1.0 Squalane 5.0 ⁇ -Olefin oligomer 3.0 Sodium hyaluronate 0.2 Hydrolyzed collagen powder 0.02 Methyl polysiloxane 0.5 Chelating agent Suitable amount of preservative (methyl paraoxybenzoate, propyl paraoxybenzoate, phenoxyethanol) Appropriate amount of pH adjuster Appropriate amount of perfume Appropriate amount Purified water balance Total 100
  • Organic fluorescent agent-containing microcapsules 5 Carboxyvinyl polymer 0.15 Hydroxyethyl cellulose 0.1 Dipropylene glycol 3 Glycerin 5 1,3-butylene glycol 7 Tri (capryl / capric) glyceryl 3 Sodium edetate 0.05 pH adjuster appropriate amount preservative appropriate amount Purified water remaining Total 100
  • the organic fluorescent agent-containing microcapsules are produced by the method described in Example 1 of WO2012 / 102397.
  • Formulation Example 8 Cream Hydroxyethylurea 15.0 Polyoxybutylene polyoxyethylene polyoxypropylene glyceryl ether (3B.0) (8E.0) (5P.0) 7.0 Sodium hyaluronate 0.15 Sorbitan monostearate1.2 Polyoxyethylene sorbitan isostearate (20.
  • the decrease in the viscosity of the acidic mucopolysaccharide over time is suppressed, and a good feeling of use with viscosity is maintained for a long time. Along with this, a decrease in the moisture retention performance and the moist or moist feeling imparting performance is also suppressed.
  • the composition for external use of the present invention has high commercial value because the properties of the acidic mucopolysaccharide are not deteriorated by distribution and storage.

Abstract

La présente invention concerne une composition pour usage externe, qui comprend (a) un mucopolysaccharide acide, (b) un composé ayant un groupe polyoxyalkylène, et (c) une hydroxyalkylurée et qui est pratiquement suffisamment protégée contre une diminution de la viscosité au cours du temps et une diminution du toucher à l'utilisation ou des performances d'humectant qui accompagnent la diminution de la viscosité.
PCT/JP2013/079077 2012-10-29 2013-10-28 Composition pour usage externe WO2014069385A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201380056741.5A CN104780902A (zh) 2012-10-29 2013-10-28 外用组合物
JP2014544486A JP6386911B2 (ja) 2012-10-29 2013-10-28 外用組成物
HK15111571.7A HK1210709A1 (en) 2012-10-29 2015-11-24 Composition for external use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012-238403 2012-10-29
JP2012238403 2012-10-29

Publications (1)

Publication Number Publication Date
WO2014069385A1 true WO2014069385A1 (fr) 2014-05-08

Family

ID=50627291

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/079077 WO2014069385A1 (fr) 2012-10-29 2013-10-28 Composition pour usage externe

Country Status (4)

Country Link
JP (1) JP6386911B2 (fr)
CN (1) CN104780902A (fr)
HK (1) HK1210709A1 (fr)
WO (1) WO2014069385A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014094902A (ja) * 2012-11-08 2014-05-22 Milbon Co Ltd 頭皮頭髪用化粧料
JP2016084337A (ja) * 2014-05-13 2016-05-19 ロート製薬株式会社 外用組成物
WO2016084709A1 (fr) * 2014-11-26 2016-06-02 小林製薬株式会社 Composition pour application externe
WO2016084708A1 (fr) * 2014-11-26 2016-06-02 小林製薬株式会社 Composition pour application externe
EP3056195A1 (fr) * 2015-02-13 2016-08-17 Vision:Organic GmbH Compositions contenant de l'acide hyaluronique et du bêta-glucane pour des applications topiques dans une cavité orale
JP2016175845A (ja) * 2015-03-18 2016-10-06 小林製薬株式会社 外用組成物
JP2017081873A (ja) * 2015-10-30 2017-05-18 花王株式会社 乳化化粧料
JP2019127460A (ja) * 2018-01-25 2019-08-01 久光製薬株式会社 ゲル状化粧料
JP2020105123A (ja) * 2018-12-27 2020-07-09 日油株式会社 水性皮膚化粧料

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018040064A1 (fr) * 2016-09-02 2018-03-08 L'oreal Composition contenant des billes aqueuses
CN111109640A (zh) * 2019-12-31 2020-05-08 华熙生物科技股份有限公司 一种含有透明质酸组合物的烟丝及其制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61180705A (ja) * 1985-02-06 1986-08-13 Shiseido Co Ltd 皮膚外用組成物
JP2006096725A (ja) * 2004-09-30 2006-04-13 Nippon Nsc Ltd 毛髪化粧料
US20060204466A1 (en) * 2005-03-08 2006-09-14 Ecolab Inc. Hydroalcoholic antimicrobial composition with skin health benefits
DE102006034530A1 (de) * 2006-07-24 2008-01-31 Beiersdorf Ag Kosmetische Formulierung mit (2-Hydroxyethyl)harnstoff und Glucosylglyceriden
JP2008285421A (ja) * 2007-05-15 2008-11-27 Q P Corp 毛髪改質浸透剤およびこれを用いた毛髪用化粧料
JP2010070526A (ja) * 2008-09-22 2010-04-02 Nippon Fine Chem Co Ltd 化粧料
JP2011236137A (ja) * 2010-05-07 2011-11-24 Chanel Keshohin Gijutsu Kaihatsu Kenkyusho:Kk 窒化ホウ素複合粉体を配合してなる化粧料組成物
JP2012512215A (ja) * 2008-12-17 2012-05-31 ロレアル Ｕｖ照射によって誘発される皮膚の褐変化を制御するための化粧方法、組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007856A1 (fr) * 1991-10-16 1993-04-29 Richardson-Vicks, Inc. GEL COSMETIQUE AQUEUX A pH FAIBLE CONTENANT DES DERIVES DE POLYACRYLAMIDE NON IONIQUE
CN1679470A (zh) * 2005-01-12 2005-10-12 凌沛学 用于化妆品的含海藻糖和透明质酸组合物及其制备方法
US8703160B2 (en) * 2005-08-25 2014-04-22 Colgate-Palmolive Company Moisturizing compositions

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61180705A (ja) * 1985-02-06 1986-08-13 Shiseido Co Ltd 皮膚外用組成物
JP2006096725A (ja) * 2004-09-30 2006-04-13 Nippon Nsc Ltd 毛髪化粧料
US20060204466A1 (en) * 2005-03-08 2006-09-14 Ecolab Inc. Hydroalcoholic antimicrobial composition with skin health benefits
DE102006034530A1 (de) * 2006-07-24 2008-01-31 Beiersdorf Ag Kosmetische Formulierung mit (2-Hydroxyethyl)harnstoff und Glucosylglyceriden
JP2008285421A (ja) * 2007-05-15 2008-11-27 Q P Corp 毛髪改質浸透剤およびこれを用いた毛髪用化粧料
JP2010070526A (ja) * 2008-09-22 2010-04-02 Nippon Fine Chem Co Ltd 化粧料
JP2012512215A (ja) * 2008-12-17 2012-05-31 ロレアル Ｕｖ照射によって誘発される皮膚の褐変化を制御するための化粧方法、組成物
JP2011236137A (ja) * 2010-05-07 2011-11-24 Chanel Keshohin Gijutsu Kaihatsu Kenkyusho:Kk 窒化ホウ素複合粉体を配合してなる化粧料組成物

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014094902A (ja) * 2012-11-08 2014-05-22 Milbon Co Ltd 頭皮頭髪用化粧料
JP2016084337A (ja) * 2014-05-13 2016-05-19 ロート製薬株式会社 外用組成物
WO2016084709A1 (fr) * 2014-11-26 2016-06-02 小林製薬株式会社 Composition pour application externe
WO2016084708A1 (fr) * 2014-11-26 2016-06-02 小林製薬株式会社 Composition pour application externe
EP3056195A1 (fr) * 2015-02-13 2016-08-17 Vision:Organic GmbH Compositions contenant de l'acide hyaluronique et du bêta-glucane pour des applications topiques dans une cavité orale
JP2016175845A (ja) * 2015-03-18 2016-10-06 小林製薬株式会社 外用組成物
JP2017081873A (ja) * 2015-10-30 2017-05-18 花王株式会社 乳化化粧料
JP2019127460A (ja) * 2018-01-25 2019-08-01 久光製薬株式会社 ゲル状化粧料
JP7150438B2 (ja) 2018-01-25 2022-10-11 久光製薬株式会社 ゲル状化粧料
JP2020105123A (ja) * 2018-12-27 2020-07-09 日油株式会社 水性皮膚化粧料
JP7127536B2 (ja) 2018-12-27 2022-08-30 日油株式会社 水性皮膚化粧料

Also Published As

Publication number Publication date
CN104780902A (zh) 2015-07-15
JPWO2014069385A1 (ja) 2016-09-08
HK1210709A1 (en) 2016-05-06
JP6386911B2 (ja) 2018-09-05

Similar Documents

Publication Publication Date Title
JP6386911B2 (ja) 外用組成物
JP5876962B2 (ja) 外用組成物
JP6430109B2 (ja) 外用組成物
JP4786630B2 (ja) 皮膚外用剤
JP5934164B2 (ja) 外用組成物
JP2021167350A (ja) 皮膚外用組成物
JP2016188258A (ja) 抗菌用組成物
JP2005060234A (ja) 皮膚外用剤
JP2017025110A (ja) 外用組成物
JP6416473B2 (ja) 外用組成物
JP2016040236A (ja) 外用剤
JP5951277B2 (ja) アゼライン酸を含有する外用組成物
JP6974952B2 (ja) 外用組成物
WO2012008457A1 (fr) Composition pour application externe
JP2005060233A (ja) 皮膚外用剤
JP5902410B2 (ja) 外用組成物
JP2012036174A (ja) 外用組成物
JP6893944B2 (ja) 皮膚外用剤
JP6709585B2 (ja) 皮膚外用剤
JP5734686B2 (ja) 皮膚外用組成物
JP2016222585A (ja) 皮膚外用剤
JP6608620B2 (ja) 皮膚外用剤
JP2016204307A (ja) 皮膚外用組成物、着色抑制剤および着色抑制方法
JP2012158567A (ja) 皮膚外用組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13851925

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2014544486

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13851925

Country of ref document: EP

Kind code of ref document: A1